Scisparc Ltd. · NASDAQ:SPRC
Scisparc — Therapix Biosciences — Seminar TASE June 2017
33 slides from Scisparc's conference presentation, Jun 29, 2017
Slide 1: Therapix Biosciences
THERAPIX BIOSCIENCES Clinical-Stage Pharmaceutical Company Focusing on Proprietary Synthetic Cannabinoids Seminar TASE June 2017
Slide 2: Forward-Looking Statements
Forward-Looking Statements ( a ‘MI statements in this communication, other than those felating to historical facts, are orwarioking statements.” “ese orwaroking statements may ineude, ut are not limited to, statements felting to out objects, pans, and stvatepes, the expected ting of tras, statements
Slide 3: Medical Cannabis
Medical Cannabis bnamolance win caPap 7538 locas Seton Sea Sand 388 ots Dot ‘Sve cpu Rony ego ow esi cn ose THERAPIX BIOSCIENCES
Slide 4: The hurdles of developing Cannabinoid drugs
The hurdles of developing Cgnnayoid drugs ’ Dr. Ascher Shmulewitz Regulatory Landscape and Unique Approach. THERAPIX BIOSCIENCES
Slide 5: Advantages of Cannabis
Advantages of Cannabis — AtjasGtance ’ Fewer pills prescribed in medical pot states Difference between annual drug doses prescribed per physician in medical marijuana states, and in states without medical marijuana laws, by drug category 1,826 fewer doses Glaucoma |35 more doses WAPO.SVWONKBLOG Sour
Slide 6: Botanical Drug Development
Botanical Drug Development> * . ’ ‘Typical Process for Conducting Research with Marijuana Step 1: Sponsor obtains pre-IND number from FDA. Step 2: Sponsor contacts NIDA or another DEA-registered source of marijuana to obtain information on the specific strains of marijuana available, so that all nec
Slide 7: Botanical Drug Development
Botanical Drug Developmen Do Cannabis companies develop a drug? * No. As long as cannabis remains a Schedule | controlled substance under the Controlled Substances Act, jumping these hurdles is impossible for the average business. There are exceptions, like GW Pharmaceuticals. Why does insurance cov
Slide 8: Rethinking Drug Development
Rethinking Drug Development ~Crowd clinical development: Real world experience -505(b)2: * Reformulation * Repositioning * Combination -Focus on KOLs and specialization (CNS). -Partner early and globally. ‘lent nano 250)and Sa) Anton: THERAPIX BIOSCIENCES
Slide 9: Rethinking Drug Development
Rethinking Drug Dévelopmeyit—™ ’ Pharmaceutical products are in general approved in one of three ways: * A New Drug Application (NDA) through the 505(b)(1) pathway * Ageneric drug using an Abbreviated New Drug Application (ANDA) through the 505(j) pathway * An over-the-counter (OTC) drug is approved
Slide 10: Compelling technology based on robust, cannabis-based science
Compelling technology based on robust, cannabis-based science Potentially cost- and time-efficient and de-risked regulatory pathway| &© Therapeutic programs address areas of high-unmet medical needs World-class scientific leadership and proven and experienced management Compelling valuation —discoun
Slide 11: Rethinking Drug Development
Rethinking Drug Development ’ Highlights: v Focus v Decades of experience v Establish clinical benefit relative to medical marijuana v Leverage Israeli eco-system v Leverage orphan indication THERAPIX BIOSCIENCES
Slide 12: Clinical Affairs
Clinical Affairs Dr. Yafit Stark Expected clinical trials in the next year. THERAPIX BIOSCIENCES
Slide 13: Therapix Biosciences pipeline
THERAPIX BIOSCIENCES Phase I/II Phase Ila Pivotal (A) Yale University (2) Hannover Medical School 2H18-2H19 TeD uopynz1jpj219UILIOD
Slide 14: Cannabis and Cannabinoid Overview
Cannabis and Cannabinoid Overview Medicinal use of cannabis and derivatives is well known* Best known agents in cannabis: THC and CBD ¥ Potential benefits shown in multiple indications: antispastic, analgesic, antiemetic, neuroprotective, anti-inflammatory and in certain psychiatric diseases ¥ Sourc
Slide 15: THERAPIX
THERAPIX BIOSCIENCES
Slide 16: Targeting Tourette Syndrome - an Orphan Disease?
Targeting Tourette Syndrome - an Orphan Disease? v Primary near-term indication for Therapix: Tourette Syndrome - A neuropsychiatric tic disorder characterized by motor and vocal tics v To date, only three drugs? have been approved by the FDA to treat Tourette Syndrome - limited use due to severe si
Slide 17: THC and PEA, a Proprietary Combination
THC and PEA, a Proprietary Combination The Entourage Effect THERAPIX 3IOSCIENC
Slide 18: Tourette Syndrome - Joint Pharma Solution THX-TS01
Tourette Syndrome - Joint Pharma Solution THX-TSO1 v Several studies suggest that cannabis and THC may be effective in the treatment of Tourette Syndrome ¥ THX-TSO1 - combines a synthetic endocannabinoid analog, PEA, with THC ¥ Taking a 505 (b)(2) regulatory strategy for FDA approval, based on Marin
Slide 19: THX-TS01 Development Plan
Tourette Syndrome- THX-TSO1 Development Plan Number of Patients 20 (cross over) First Patient In (Date) 4Q-16 30-17 Last Patient In (Expected Date) est 68 Expected Data (Expected Date) ean at , Randomized, double-blind, placebo penetra Pianeta Open-label; single center controlled, cross-over study;
Slide 20: THX-TS01 - Additional Opportunities
THX-TSO1 - Additional Opportunities Antibacterial Therapy ¥ Antimicrobial resistance has been defined as a global threat? ¥ Urgent unmet need for new anti-bacterial agents? THC may possess antibacterial properties, which were assessed in number of clinically relevant applications? ¥ Therapix intends
Slide 21: THERAPIX
THERAPIX BIOSCIENCES
Slide 22: Mild Cognitive Impairment (MCI) and Alzheimer's Disease
Mild Cognitive Impairment (MCI) and Alzheimer’s Disease ¥ In 2015, there were an estimated 46.8 million people with dementia worldwide and is estimated to increase by 2030 to 74.7 million? ¥ The global societal economic cost of dementia for 2015 is estimated at $818 billion, a 35% increase from the
Slide 23: Cannabis and Cognition
Cannabis and Cognition ¥ Cannabis has been shown to cause long-term cognitive deficits in chronic users manifested as impairment in attention, memory or executive functions ¥ Paradoxically, Ultra-Low Doses of THC have been shown to prevent and reverse cognitive decline in preclinical trials1 as demo
Slide 24: Mild Cognitive Impairment (MCI) - BrainBright Solution THX-ULD01
Mild Cognitive Impairment (MCI) - BrainBright Solution THX-ULDO1 ¥ Recent pre-clinical research demonstrates Ultra-Low Doses of THC can prevent cognitive impairment ¥ THX-ULDO1 - Therapix is developing a unique drug based on an FDA approved synthetic cannabinoid for delaying memory loss and potentia
Slide 25: Financial Affairs
Financial Affairs Mr. Josh Blacher Competitive Landscape, Analyst coverage, and financial perspective THERAPIX BIOSCIENCES
Slide 26: Cannabinoid stocks to choose from on the Nasdaq
abinoid ST Only 4 To Choose From On The Nasdaq TRPX ZYNE INSY GWPH THERAPIX
Slide 27: Competitive Landscape
Competitive Landscape (Huron Extract) Marinol Cesamet Sativex Syndros Epidiolex | THX-Tso1 | THX-ULDO1 (Aronabino!) | (nabilone) | (nabiximots) | (dronabino! | (cannabidiol) | (dronabinol + | (dronabinol) coral solution) PEA) Manufacturer | AbbVie Meda GW Pharma Insys GW Pharma | — Therapix Therapix
Slide 28: Numerous Short- and Long-Term Milestones & Catalysts
Numerous Short- and he Milestones & Catalysts | US-Based CFO Top-Line Data: Top-Line Data: Top-Line Data: Appointed Phase Ila Study in Phase Ila Study in Phase I/Il PKPD TS at Yale TS at Hannover Study in MCI m— | ey et | 3017 4Q17 1Q 2018 Initiate Phase Ila Initiate Phase N. America-Based Business
Slide 29: Strong Scientific Advisory Board
Strong Scientific Advisory Board Prof. Michael Davidson, rot Raphael Mecholam rot Jones einen Prot Kien Merve Nien Grol me » ved Payton ole henchmen Cpe reais yey imag pisolty Fnnova Media Stat Se cae Faculty of Medicine of the = Served as Director of the Child Germany Department of Psychiatry of th
Slide 30: Experienced Management Team
Experienced Management Team Dr. Ascher Shmulewitz, Chairman = Prolific inventor and serial entrepreneur in biomedical technologies = Has founded over two dozen life science companies and led multiple companies to successful exits Dr. Elran Haber, CEO “Served more than 10 years as Chairman and on Boa
Slide 31: Board of Directors
Board of Directors THERAPIX BIOSCIENCES
Slide 32: Summary
Summary vy Focused on high value CNS indications with unique combinations, formulations and delivery methods ¥ Two indications with potential for shorter regulatory paths due to: Orphan Drug Designation (Tourette's) and 505(b)(2) pathway using approved active ingredients (Tourette's, MCI) v Phase Il
Slide 33: Therapix Biosciences Ltd. contact details
Therapix Biosciences Ltd. 5 Azrieli Center (Square Tower) 27 Fl. Tel-Aviv 6702501, Israel Tel: +972-3-6167055 info@therapixbio.com www.therapixbio.com THERAPIX BIOSCIENCES